Claims
- 1. A method for the treatment of medication-, substance-, disease-, and/or other medical condition-related sexual dysfunction comprising the administration of a therapeutically effective amount of at least one acetylcholinesterase inhibitor to an individual, wherein:
a) said at least one acetylcholinesterase inhibitor is not co-administered with histamine receptor agonists; and b) said method excludes: i) the treatment of physiologic male erectile dysfunction comprising the administration of galanthamine; and ii) the treatment of psychogenic/psychological impotence comprising the administration of neostigmine bromide or neostigmine methyl sulfate.
- 2. The method according to claim 1, wherein said sexual dysfunction is selected from the group consisting of reduced sexual desire, delayed or inhibited ejaculation, delayed orgasm, anorgasmia, and erectile disorders.
- 3. The method according to claim 1, wherein said acetylcholinesterase inhibitor is selected from the group consisting of donepezil, galantamine, tacrine, eptastigmine, physostigmine, rivastigmine, metrifonate, neostigmine, huperzine A, and combinations thereof.
- 4. The method according to claim 3, wherein two acetylcholinesterase inhibitors are selected.
- 5. The method according to claim 3, wherein three acetylcholinesterase inhibitors are selected.
- 6. The method according to claim 3, wherein four acetylcholinesterase inhibitors are selected.
- 7. The method according to claim 3, wherein five acetylcholinesterase inhibitors are selected.
- 8. The method according to claim 3, wherein six acetylcholinesterase inhibitors are selected.
- 9. The method according to claim 3, wherein seven acetylcholinesterase inhibitors are selected.
- 10. The method according to claim 3, wherein eight acetylcholinesterase inhibitors are selected.
- 11. The method according to claim 3, wherein nine acetylcholinesterase inhibitors are selected.
- 12. The method according to claim 1, wherein said acetylcholinesterase inhibitor is administered orally, transdermally, nasally, or mucosally.
- 13. The method according to claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, wherein said acetylcholinesterase inhibitor(s) is co-administered with an agent selected from the group consisting of sildenafil, tadalafil, vardenafil, cyproheptadine, tradodone, nefazodone, mianserin, mirtazapine, granisetron, yohimbine, amantadine, dextroamphetamine, pemoline, methylphenidate, bupropion, buspirone, ginkgo biloba, and various combinations of said agents.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of provisional patent application Serial No. 60/371,666, filed Apr. 10, 2002, which is hereby incorporated by reference in its entirety, including all figures, tables, and drawings.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60371666 |
Apr 2002 |
US |